Treatment of myelogenous leukemia: current status and investigational options.
Kantarjian
H M
HM
Department of Hematology, M.D. Anderson Cancer Center Houston TX, 77030, USA.
O'Brien
S
S
Anderlini
P
P
Talpaz
M
M
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003561:Cytarabine / Q000627:therapeutic use; D006248:Harringtonines / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D000077863:Homoharringtonine; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000628:therapy*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D012307:Risk Factors; D016879:Salvage Therapy; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D006248:Harringtonines; D007155:Immunologic Factors; D016898:Interferon-alpha; D003561:Cytarabine; D000077863:Homoharringtonine